Abstract 241P
Background
The aims of this study were to investigate the genetic alternations of locally advanced cervical cancer and to elucidate the associations among clinico-pathological factors, genomic alterations and clinical outcomes of the patients receiving concurrent chemo-radiotherapy (CCRT). We performed the targeted sequencing for somatic mutations across the hotspot regions of 50 cancer-related genes using biopsy specimens.
Methods
Seventy-six patients diagnosed as FIGO Stage III to IVA cervical cancer underwent radiation therapy or CCRT at National Cancer Center Hospital between January 2008 and December 2017. All the patients received external beam radiation therapy and brachytherapy. The most of chemotherapy regimen was cisplatin. Genomic DNAs extracted from formalin-fixed and paraffin-embedded tumor tissues were subjected to the analysis using an Ion AmpliSeq TM Cancer Hotspot Panel v2. Six patients were disqualified from this study because of low quality DNA. Oncogenic or pathogenic variants registered in the OncoKB and the ClinVar databases were defined as mutations. In the present study, gene aberrations with evidence levels 1A-3A were judged as actionable mutation for molecular targeted drugs. HPV infection was detected by in-situ hybridization and genotypes were determined by Sanger sequencing.
Results
Seventy patients were enrolled in this study. Sixty-five patients (93%) had squamous cell carcinoma. Pathogenic mutations were detected in 47 cases (67%); frequencies of gene alterations in PIK3CA (51%), FBXW7 (10%), PTEN (7.1%) and TP53 (5.7%). The clinical factor associated with poor survival was the tumor diameter. Cox regression analysis showed the tumor diameter larger than 70mm were associated with shorter progression-free survival (PFS) (Hazard ratio = 2.96, P = 0.0048) in multivariate analysis. Patients infected without HPV16/18 had poor PFS than those with HPV 16/18 (Log-rank P = 0.025). TP53 mutants were correlated with poor PFS (Log-rank P = 0.044). Thirty-seven patients (53%) have actionable genomic alternations.
Conclusions
Larger tumor diameter, non HPV16/18 and TP53 mutants correlated with worse outcomes to CCRT in the Japanese patients with locally advanced cervical cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
237P - PARP inhibitor in platinum resistant ovarian cancer: Single center real world experience
Presenter: Saphalta Baghmar
Session: Poster display session
Resources:
Abstract
238P - Laparoscopic cytoreduction in low disease burden, advanced-stage ovarian cancers: Experience from a tertiary cancer center
Presenter: Vikas Gupta
Session: Poster display session
Resources:
Abstract
239P - Impact of counseling on patient reported sexual adjustment following chemoradiation and brachytherapy for cervical cancer
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
240P - Morbidity and mortality of cervical cancer in the Republic of Kazakhstan
Presenter: Almagul Zhabagina
Session: Poster display session
Resources:
Abstract
242P - Impact of combined interstitial and intracavitary brachytherapy in locally advanced cervical cancer: A survival and toxicity profile assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
243P - Cervical cancer screening in sub-urban area of Banten and factor associated with uptake of screening
Presenter: Prio Wibisono
Session: Poster display session
Resources:
Abstract
245P - Factors influencing adherence to cryotherapy following positive VIA result as cervical cancer prevention in Temanggung, Central Java, Indonesia
Presenter: Herindita Puspitaningtyas
Session: Poster display session
Resources:
Abstract
246P - The main of reasons of advanced stage cervical cancer in Uzbekistan
Presenter: Zakhirova Nargiza
Session: Poster display session
Resources:
Abstract
247P - Role of ADC values in assessing response after chemoradiotherapy in cervix cancer and in identifying residual disease
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
248P - Retrospective review of metastatic carcinoma of cervix from a tertiary cancer institute of south India
Presenter: Arkoprovo Halder
Session: Poster display session
Resources:
Abstract